Last updated: July 16, 2026
Astellas Pharma Inc. v. Sawai Pharmaceutical Co., Ltd., 1:16-cv-00954 (D. Del.) is an ANDA-related patent infringement case in which Astellas asserted patent rights against Sawai. The litigation’s business impact is determined by (i) which patents Astellas asserted, (ii) the court’s claim construction and dispositive rulings, (iii) the final infringement/validity outcomes, and (iv) any FDA 30-month stay and post-judgment design-around effects.
Litigation posture, dispositive outcome, and Orange-Book/patent coverage cannot be accurately summarized from the case caption alone. A complete litigation summary requires the docket entries and the asserted-patent list (complaint/joint appendix), and those details are not provided in the prompt.
What is Astellas Pharma Inc. v. Sawai Pharmaceutical Co., Ltd. 1:16-cv-00954 about?
Short answer: This is an ANDA patent infringement matter filed by Astellas against Sawai, indexed as 1:16-cv-00954, but the specific active ingredient, product, and asserted patent numbers are not stated in the provided input.
What lawsuit type usually applies in 1:16-cv-00954 ANDA filings?
Typical structures in this docket class include:
- 35 U.S.C. § 271(e)(2) infringement tied to an ANDA submission.
- Allegations of infringement of one or more listed Orange Book patents, often spanning composition, formulation, method-of-use, and/or manufacturing.
- Validity challenges by the ANDA filer (Sawai) and corresponding written description/enablement/§112 and anticipation/obviousness contentions.
What patents are usually asserted in these cases?
For a litigation summary that is actionable for licensing, entry risk, and freedom-to-operate, the asserted patent list is required:
- Patent numbers asserted in the complaint (and counts per patent)
- Whether the case includes method-of-use claims
- Whether the asserted patents are formulation/composition versus process claims
- Whether the case includes a Hatch-Waxman Paragraph IV certification framework
Those items are not included in the prompt.
Which patents did Astellas assert in 1:16-cv-00954 and what were the claims?
Short answer: The asserted patents and their claim categories are not provided.
How to map asserted patents to entry-risk levers
For ANDA litigation, decision-grade analysis depends on patent type:
- Composition-of-matter patents often drive the core statutory injunction leverage.
- Formulation patents can constrain generic product design, even if some composition claims are invalidated.
- Method-of-use patents create narrower generic launch constraints but still can block some indications.
- Manufacturing/process patents can require design-around at scale.
No patent numbers or claim types are provided.
What did the court decide in Astellas v. Sawai (1:16-cv-00954)?
Short answer: Dispositive rulings, claim construction, and final judgment status are not available from the case caption alone.
Which rulings determine generic entry timing
Litigation can change market access through:
- Claim construction orders narrowing or broadening claim scope.
- Summary judgment on invalidity or non-infringement.
- Final judgment granting or denying infringement and validity.
- Permanent injunction or a limited injunction (by claim scope or indication).
No court decision details are provided.
Did Sawai get a 30-month stay, and when did exclusivity barriers lift?
Short answer: 30-month stay timing cannot be determined without:
- the ANDA filing date,
- the paragraph IV certification date,
- any court schedule milestones and injunction entry timelines,
- and any FDA approval date.
None of these dates are included in the prompt.
What Paragraph IV certifications were at issue in Astellas v. Sawai?
Short answer: The Paragraph IV certification framework is not described in the input.
Why certification type changes litigation leverage
Common certification patterns:
- Paragraph IV to one or more patents listed in the Orange Book.
- Certification type (IV vs. I/II/III) impacts whether FDA can approve immediately or must wait for patent expiry or court outcomes.
- Multiple patents across categories (drug substance vs. formulation vs. method) can create “mixed” results.
No certification details are provided.
What is the Orange Book status of the patents involved in 1:16-cv-00954?
Short answer: Orange Book listings tied to the asserted patents are not provided.
How to interpret Orange Book status in practice
For litigation-driven freedom-to-operate:
- Confirm whether each asserted patent is listed for the NDA referenced in the ANDA.
- Confirm the “expiration” and whether the court judgment resolves listed patents.
- Identify whether additional unasserted Orange Book patents could block launch even if some asserted patents fall.
No Orange Book data is provided.
How strong is Astellas’ patent estate for the underlying product in 1:16-cv-00954?
Short answer: Strength and breadth cannot be assessed without the asserted patent numbers and their remaining terms.
Patent estate strength metrics used in these matters
Actionable metrics include:
- Remaining life of each asserted patent at the time of judgment.
- Number of independent claims surviving dispositive motions.
- Prior art density and whether invalidity theories were adopted.
- Whether design-around substitutes were blocked by formulation/process claims.
No asserted-patent list or outcomes are provided.
What generic entry risks exist for Sawai after the case outcome?
Short answer: Entry risk depends on the court’s infringement/validity findings and whether Sawai received or lost any FDA approval path.
Post-judgment design-around pathways
Potential pathways after a partial win/loss:
- Reformulate to avoid formulation claims while keeping composition.
- Change dosing or regimen to avoid method-of-use constraints.
- Revise manufacturing/process parameters to avoid method/process infringement.
No judgment content is provided, so risks cannot be quantified.
Are there related settlements or companion cases tied to 1:16-cv-00954?
Short answer: Settlement status and any companion litigation cannot be determined from the provided input.
How settlement terms typically affect market entry
Where a settlement exists, it can include:
- Launch date commitments
- Royalty structures
- Covenant not to sue on specific design-arounds
- Dismissal with prejudice after a consent judgment
No settlement details are provided.
How does this case compare with other Astellas ANDA litigations against Sawai?
Short answer: No related-case set is provided, so comparison is not possible from the prompt.
Comparison framework
A robust compare-and-contrast uses:
- same active ingredient family and same patent clusters,
- different court outcomes,
- differences in claim construction positions,
- and different FDA approval/launch outcomes.
No comparison universe is provided.
Key Takeaways
- Case identity is clear; litigation substance is not. Astellas v. Sawai, 1:16-cv-00954, is an ANDA patent infringement matter in which Astellas asserted patent rights against Sawai.
- A complete litigation summary requires asserted patent numbers, procedural history, and court disposition. Those inputs are not present in the prompt.
- Entry-risk conclusions depend on the final judgment and Orange Book-patent mapping. Neither the decision nor the Orange Book listing details are provided.
FAQs
- What patents are typically asserted by Astellas in ANDA cases involving Sawai?
- How does a dismissal or claim-construction order change FDA approval timelines in ANDA Paragraph IV litigations?
- What does “limited injunction” mean in Hatch-Waxman cases and how is it implemented?
- How do unasserted Orange Book patents affect generic launch even after an infringement loss?
- What role do expert claim charts and non-infringement theories play in method-of-use versus formulation cases?
References
- Astellas Pharma Inc. v. Sawai Pharmaceutical Co., Ltd., No. 1:16-cv-00954 (D. Del.).
